Shenzhen Hybio Pharmaceutical (revision 23)

Shenzhen Hybio Pharmaceutical Co., Ltd. (trading as HYB; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.^[1][2]

The organisation is one of twenty-two covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Shenzhen in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.^[1] Shenzhen is inside the Pearl River Delta manufacturing belt, and the organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.^[2]

The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.^[2][1]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5] That correspondence is a minimum requirement rather than an achievement, and it is recorded only because traceability fails often enough elsewhere in this sector to make its absence the more common finding.

Water content by Karl Fischer titration appears on the certificates described in the submitted set more often than for most entities covered here, and peptide content is reported on a separate line from chromatographic purity across a substantial part of it.^[5][6] Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation.

What the record does not establish is the physical arrangement of manufacture, whether synthesis is performed in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.^[2][7]

The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure, and in places a reference to a drug master file said to be held with a regulator elsewhere. Whether such a file exists, and what it covers, is not established by any source available to this wiki, and a reader should treat the reference as a claim until it is.^[2]

Reports on HYB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported area percent figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point.^[5]

Agreement of that kind is a weaker finding than it appears. It establishes that two measurements of one sample agreed; it establishes nothing about the lot the sample was drawn from, because none of these reports arose from a blind sampling procedure with a documented chain of custody.^[5] The more informative observation is the documentary one recorded above: where water and peptide content accompany the purity figure, a second laboratory can reproduce the determination rather than merely repeat it.^[6]

Catalogue lines dispatch from held stock, and the organisation's own material states a same-day or next-working-day dispatch window on listed items.^[2] Bulk active-ingredient quantities and custom synthesis are quoted individually, with a timeline stated on the quotation; submissions describe delivery at or inside that date.^[5]

Minimum order quantity is a single vial on catalogue lines. Bulk and custom work carry their own minima, quoted with the timeline.

The certificate issued with an order names the lot, the compound, the determination method and the release date, and reports area percent purity alongside water content and peptide content as separate lines.^[5][6] A second certificate covering an earlier purchase is issued from the organisation's records against the lot number.

To obtain the batch record behind a certificate, quote the lot identifier printed on the vial and ask for the analytical conditions — gradient, column chemistry, detection wavelength — together with the mass-confirmation result. With water and content already on the document, those are what remain before an independently obtained figure can be set against the stated one. For an active-ingredient line, ask in addition which assay basis the specification sheet reports against.

The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-two organisation articles, per the discussion linked from the talk page.

Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.

Go to the HYB catalogue →

The PeptidePedia tally records 968 self-reported submissions concerning HYB to July 2026. What recurs across them is certificate completeness — water and content determinations described as present on the document as issued rather than supplied on request — together with agreement between a reorder and the original order of the same line.^[4] The tally is self-selected and measures reception rather than quality, and it is not comparable with the figure any other community publishes for the same organisation.^[4]

The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.